Epithalon is a synthetic four-amino-acid peptide studied in Russian longevity research for effects on telomerase; this page collects reported examples and weighs the evidence honestly, for educational use only, not medical advice.
Standard Access: This compound's three paid filesAll-Access Lifetime: all 55 guides + every printableEducational content only
Epithalon Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Epithalon at a glance
What it is
Epithalon (Epitalon, AEDG), the synthetic tetrapeptide Ala-Glu-Asp-Gly, modeled on the pineal extract epithalamin
Researched for
Telomerase activity, cellular aging and pineal/circadian regulation in cell and animal models
Plasma half-life
Very short - minutes; no established human pharmacokinetic profile
Regulatory status
Not FDA-approved and not an approved medicine anywhere; research use only
Educational reference. This page does not publish dose ranges or reconstitution arithmetic.
What it is / mechanism
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed from epithalamin, a pineal-gland extract studied by Vladimir Khavinson's group in St Petersburg. The proposed mechanism belongs to the Khavinson 'peptide bioregulator' framework, in which short peptides are described as binding directly to specific DNA sequences in gene promoter regions and thereby modulating transcription. In this model Epithalon is reported to induce expression of the telomerase catalytic subunit (hTERT), increasing telomerase activity and, in cell culture, telomere elongation. It has also been described as influencing melatonin secretion and circadian regulation via pineal activity, and as having antioxidant effects in animal models. It is worth stating plainly that the direct DNA-binding mechanism proposed for peptide bioregulators is not a broadly accepted model in mainstream molecular biology, and the supporting work comes overwhelmingly from a single research tradition.
Researched effects
In cell-culture research Epithalon has been associated with induction of telomerase, telomere elongation, and extension of fibroblast replicative capacity beyond the usual Hayflick limit. In rodent studies chronic administration has been reported to extend mean lifespan and reduce spontaneous tumour incidence. These are reported findings in cells and animals. The critical limitation, which any honest summary must state, is that there is no peer-reviewed, independently replicated controlled trial in humans demonstrating that Epithalon meaningfully lengthens telomeres or extends lifespan - no completed human trial has measured telomere length before and after administration under controlled conditions. Nothing here is a promise of efficacy or a personal recommendation.
Evidence & regulatory status
Evidence base: the most-cited primary work is Khavinson, Bondarev and Butyugov (2003) in the Bulletin of Experimental Biology and Medicine, reporting telomerase induction and telomere elongation in human fetal fibroblasts, with a companion report of roughly ten additional population doublings. Rodent lifespan and tumour-incidence studies followed. A 2025 independent in-vitro study also reported concentration-dependent telomere-length increases in human cell lines.
A caution on source concentration: the literature is large but narrow - the great majority originates from Khavinson's own laboratory and Russian collaborators, and independent Western replication remains limited. Human clinical evidence for the anti-aging claims commonly made online is effectively absent.
Regulatory status: Epithalon is not FDA-approved and is not an approved medicine. Material supplied as Epithalon is for laboratory and research purposes only; described dosing reflects reported research and community protocols, not clinical guidance.
Research timeline
Dated milestones taken from the primary records: the molecule's discovery, its first registered human study, the trials that shaped the evidence and the regulatory decisions. Each entry links to the record it comes from.
Among the earliest papers PubMed indexes under the compound's names (search of 3 Oct 2026): Khavinson's St Petersburg institute reports that fruit flies exposed to the synthetic tetrapeptide during development lived 11–16% longer as adults. PMID 11087911
A study in 50 female CBA mice treated from six months of age until death reports a 5.3% longer mean survival with the pineal tetrapeptide than with saline, and fewer spontaneous tumours. PMID 11163623
Khavinson's group reports giving Epitalon to patients with degenerative retinal disease (retinitis pigmentosa), with a "positive clinical effect in 90% of the cases", alongside data in Campbell rats. The abstract gives no patient count or comparison group, although PubMed indexes the paper as a controlled clinical trial. PMID 12195242
In female SHR mice (54 per group), Epitalon does not change mean lifespan; the paper reports a 13.3% longer life for the last 10% of survivors and fewer chromosome aberrations in bone marrow. PMID 14501183
The telomerase paper: added to telomerase-negative human fetal fibroblasts in culture, it induced the telomerase catalytic subunit, telomerase activity and telomere elongation (Khavinson, Bondarev, Butyugov). PMID 12937682
A human study often quoted for Epithalon used a different substance: Khavinson and Morozov followed 266 elderly people for 6–8 years after courses of Epithalamin, the pineal extract, and Thymalin. PMID 14523363
The same laboratory reports that fetal lung fibroblasts treated with Epithalon at the end of their lifespan regained early-passage telomere length and made 10 extra divisions beyond the untreated cells. PMID 15455129
A Russian-language paper reports that both Epithalamin and Epitalon raised night-time melatonin in elderly people with reduced pineal function, and in old monkeys. The abstract gives no participant numbers or effect sizes. PMID 17969590
A laboratory outside the original group, at Brunel University London, reports that Epitalon lengthened telomeres in human cells: in normal epithelial cells and fibroblasts through more telomerase, and in two breast-cancer cell lines through the alternative (ALT) pathway. PMID 40908429
The journal publishes a correction to that Brunel paper. PMID 41240216
FDA's page on compounding safety risks, as updated on this date, lists epitalon among substances that had been in Category 2 and whose nominations were withdrawn, citing possible immunogenicity, aggregation and impurities and no safety information for the proposed route. FDA · compounding safety risks, Apr 22, 2026
Epitalon goes before FDA's Pharmacy Compounding Advisory Committee for the pharmacy-compounding (503A) list, evaluated for insomnia; FDA's briefing document concludes that the balance of criteria weighs against listing it. No minutes or vote were posted by 4 Oct 2026. FDA · PCAC briefing document, Jul 23–24, 2026
Records checked Oct 3, 2026
Claims at a glance
The claims most often made about this compound, each with the strongest kind of evidence we found for it. The grade says what was studied, not whether the claim is true; the line beside it says what that study showed.
Lengthens telomeresCell or tissue studies only. Telomerase activity and telomere elongation in cultured human cells (2003); no study found measured telomere length in a treated animal or person. PMID 12937682
Extends lifespanAnimal studies only. Fly and mouse results that run both ways; the human mortality figures that circulate belong to epithalamin, a bovine pineal extract, not this peptide. PMID 14501183
Restores melatonin and the sleep rhythmHuman, non-randomised. One study of 75 women, from the institute that developed the peptide: changes only where melatonin was already low, measured in urine and blood cells rather than sleep. PMID 33280326
Prevents cancerAnimal studies only. Mouse results disagree from strain to strain and dose to dose on overall tumour rates; no human data. PMID 16634527
Improves eyesight and retinal healthHuman, non-randomised. One unmasked study in an inherited eye disease, retinitis pigmentosa, from the originating institute; its only human efficacy data, not independently replicated. PMID 12195242
Restores hormone and blood-sugar balanceAnimal studies only. Old rhesus monkeys only; young animals moved the other way, and values drifted back toward baseline within a month of stopping. PMID 15664732
The reasoning behind each grade, study by study, is in this guide's Benefit & Outcome Review.
Grades checked Oct 5, 2026
A printable reference sheet with the compound's key facts, storage guidance and a vial record comes with All-Access Lifetime.
Half-life & pharmacokinetics
Epithalon is a very small tetrapeptide and is cleared from plasma rapidly, on the order of minutes; no established human pharmacokinetic profile has been published. As with other short peptide bioregulators, reported effects are attributed to downstream transcriptional changes rather than sustained plasma levels - which is the stated rationale for short daily courses. It should be noted that this rationale is an inference from the proposed mechanism rather than a conclusion from human PK data.
Reported side effects & toxicology
Reported side effects are sparse, with injection-site reactions the most commonly mentioned issue and the compound generally described as well tolerated in the animal and small-scale studies available. This apparent cleanliness should be read with care: the absence of reported adverse effects in a literature this narrow, this concentrated in one research group, and this thin on controlled human data is weak evidence of safety rather than strong evidence of it. Long-term human safety has not been established, and theoretical concerns about upregulating telomerase - a pathway also relevant to tumour cell immortality - are raised in the broader literature. These are reported observations, not an exhaustive safety profile, and nothing here is medical advice.
Storage & handling
Lyophilized (unreconstituted) vials are typically stored refrigerated and protected from light; the sealed powder is generally described as stable at room temperature for short periods before use.
After reconstitution, keep refrigerated at about 2-8 C, protect from light, and use within a few weeks; do not freeze and avoid shaking. Larger course-sized vials are held reconstituted across a course, so storage conditions matter more here than for single-use amounts.
References
Key sources include Khavinson, Bondarev and Butyugov (2003) in the Bulletin of Experimental Biology and Medicine on telomerase induction and telomere elongation in human fetal fibroblasts; Bondarev (2004) on extended fibroblast population doublings; rodent lifespan and tumour-incidence studies from the same research tradition; and a 2025 independent in-vitro report on telomere length in human cell lines. Readers should weigh the concentration of this literature in a single research group, and the absence of controlled human trials, when interpreting claims about this compound.
Evidence File
Epithalon Evidence File: An Orphan-Drug Record, Microgram Human Doses, and a Corrected 2025 Replication
Epithalon carries one of the most confidently cited evidence bases in the peptide market and one of the least examined. This file goes to the primary records instead of the summaries: a regulatory file held by a national agency, the two published human studies and what they actually specified, the most-cited mouse experiment read line by line, and the 2025 independent cell-culture study together with the publishing history that followed it. Every registry search is named so a reader can repeat it, and each circulating figure is traced back to the paper it came from before it is graded. Where the record is deflationary, this file says so first rather than last.
FDA orphan record 312010: Epitalon, retinitis pigmentosa, designated then withdrawn
Published human doses were 5 micrograms per eye and 0.5 mg per day sublingual
Flagship mouse study: mean lifespan and total tumour incidence both unchanged
The 2025 independent study was corrected in November 2025, all three figures replaced
Orphan designation 312010: the regulatory file this compound actually has
The trial-registry absence, stated exactly and no wider
The two human studies, with the doses put back in
The arithmetic between the published human doses and the community protocol
The most-cited mouse study says the opposite of the headline it is used for
The 2025 independent study, and the correction printed ten weeks later
Four circulating figures, traced back to the papers they came from
What would actually move this compound to a higher grade
8 more sections in the Evidence File for Epithalon
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Epithalon for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Sourcing File
Epithalon Sourcing File: Two Molecules, One Exact Mass, and the Certificate That Cannot Tell Them Apart
Generic certificate advice does not carry over to this peptide. Its four residues can be rearranged and re-linked into molecules that share its formula and its exact mass, so the identity line most certificates print settles less than it appears to; its side-chain chemistry breaks a detection method that certificates routinely quote; and its charge profile pushes the usual salt-correction rule of thumb in the wrong direction. This file works through the registry identifiers, the three compound-specific mislabelling routes, the counterion arithmetic with the numbers shown, and a worked line-by-line read of a certificate.
EADG shares the formula and the exact mass, so mass alone cannot exclude it
No aromatic residue, so a 280 nm purity chromatogram cannot detect this peptide
A mono-TFA salt puts a 77.4 percent floor under net peptide content
CAS 307297-39-8 is the peptide; 64082-79-7 is an extract number PubChem merged in
The identity block, and the CAS number on the same page that is not this molecule
EADG: the impostor with the identical exact mass
The gamma-linked isomer, and the analogues sold under premium-sounding names
Salt form and net peptide: the arithmetic, and why the usual rule of thumb over-corrects here
The 280 nanometre problem, and why a clean-looking C18 peak may mean nothing
A worked line-by-line read of an Epithalon certificate
What the certificate does not cover, and what this channel has actually been found to contain
7 more sections in the Sourcing File for Epithalon
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Epithalon for $14 — or every compound in the library, plus the printable reference sheets, for $99.
The sections above this one stay free to read without an account.
Benefit & Outcome Review
Epithalon Benefit and Outcome Review: Seven Claims Graded, With Human Evidence Kept Separate
Each claim made for Epithalon is taken one at a time here, and human, animal and cell-culture evidence are listed separately and never added together. Where a claim has no human evidence, that is the first line of the entry rather than a footnote at the end. The review also collects the things this literature reports that promotional summaries leave out: which subjects failed to respond, how quickly measured effects reversed after treatment stopped, where two studies point in opposite directions, and which widely quoted outcome numbers were generated with a different substance entirely.
The 28 percent mortality figure belongs to a bovine pineal extract, not this peptide
Melatonin effects are reported only where melatonin was already low
Monkey glucose values drifted back toward baseline a month after stopping
No located study has measured telomere length in a treated animal or person
The grading rules, and the claim the compound is actually sold on
Lifespan: no human data, and an animal record that runs both ways
Melatonin and circadian rhythm: the strongest human claim, and what it did not measure
Cancer: rodent results that point in opposite directions, and one that points inward
Metabolic and endocrine restoration: old animals only, and it washed out
Antioxidant effects, and an attribution problem inside the source paper
Vision: the only human efficacy data this compound has
Safety, pharmacokinetics, and what the reported cleanliness actually rests on
8 more sections in the Benefit & Outcome Review for Epithalon
Unlock the Evidence File, Sourcing File and Benefit & Outcome Review for Epithalon for $14 — or every compound in the library, plus the printable reference sheets, for $99.
Quick answers about guide scope, access, and educational use context.
What is Epithalon?
Epithalon (Epitalon, AEDG) is a synthetic tetrapeptide - Ala-Glu-Asp-Gly - derived from the pineal extract epithalamin and studied by Vladimir Khavinson's group for effects on telomerase, cellular aging and circadian regulation. It is not FDA-approved and is supplied for research use only.
Does Epithalon actually lengthen telomeres in humans?
There is no peer-reviewed, independently replicated controlled human trial showing that it does. Telomerase induction and telomere elongation have been reported in cell culture, and lifespan extension in rodents, but no completed human trial has measured telomere length before and after administration under controlled conditions. Claims of proven human anti-aging effects go well beyond what the evidence supports.
Why is the Epithalon evidence base considered narrow?
The literature is large in volume but concentrated: the great majority originates from Khavinson's own laboratory and Russian collaborators, and independent Western replication remains limited. The proposed mechanism - short peptides binding DNA promoter regions directly to regulate transcription - is also not a broadly accepted model in mainstream molecular biology. Both facts are worth knowing when reading confident claims about this compound.
Is there an established Epithalon dose or cycle?
No. Community protocols commonly describe short daily courses repeated once or twice a year; that cyclical pattern reflects how the original Russian studies were structured, not an established pharmacological requirement. There is no established human dose, this page does not reproduce the amounts that circulate, and nothing here is a recommendation.
Does this page tell me how much Epithalon to use?
No. The amounts shown are examples reported in research and community settings, provided for educational context. This page does not recommend a personal dose, route or frequency and is not medical advice. The controlled human evidence behind those amounts is thin.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
A certificate of analysis (COA) is a laboratory’s report on one sample of one batch. The single most useful thing to know about it is that purity and identity are two separate results that fail in different ways. A high purity figure says the sample was mostly one substance; it does not say that substance was Epithalon. Identity — normally a mass-spectrometry result matching the expected molecular weight — is what establishes what the material actually is, and a certificate reporting purity alone has not answered that question.
Two further limits are worth holding onto. Mass per vial is its own test: a vial can be 99% pure and still contain less material than the label claims. And sterility, endotoxin, heavy metals and residual solvent screening are separately commissioned tests, usually priced individually — so a “third-party tested” badge asserts none of them unless the certificate names them. Check that the batch or lot number on the document matches the vial in front of you; an unmatched certificate describes someone else’s material.
Medibact does not test, endorse or resell peptides, and publishes no rating of any laboratory. How to read a peptide certificate of analysis walks through the document section by section, and what each COA field establishes covers the field-by-field detail and the laboratories that publish their methods.
You’ll need bacteriostatic water
The diluent for reconstituting Epithalon
Reconstitution is volume arithmetic — it assumes a lyophilized vial is dissolved in bacteriostatic water, which is sterile water preserved with 0.9% benzyl alcohol. The preservative is what allows a vial to be entered more than once; plain sterile water carries none and is single-entry by design. Medibact supplies USP-grade Bacteriostatic Water for Injection in a 30 mL multi-dose vial, produced in an FDA-registered U.S. facility and shipped from the United States, for research use only. One 30 mL vial covers 30 reconstitutions at 1 mL each, 15 at 2 mL, or 10 at 3 mL — division only, not a dosing recommendation.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
